SCHEMBL4152170

SCHEMBL4152170

O=C(NCCc1ccnc(Cl)c1)c1ccnc2[nH]c(-c3ccco3)nc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 4/20 0.47
CACNA1B Q00975 4/20 0.45
APBA1 Q02410 4/20 0.45
NAMPT P43490 1/20 0.41
ALDH1A1 P00352 6/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
ADORA3 P0DMS8 4/20 0.40
ADORA2A P29274 4/20 0.40
ADORA1 P30542 4/20 0.40
MAPT P10636 4/20 0.40
THRB P10828 3/20 0.40
POLB P06746 3/20 0.40
NPSR1 Q6W5P4 3/20 0.40
LMNA P02545 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 2/20 0.40
USP2 O75604 2/20 0.40
HPGD P15428 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4150171 0.88 GSK3B (0.47) GSK3BCACNA1BAPBA1NAMPTALDH1A1
SCHEMBL4164633 0.88 GSK3B (0.47) GSK3BCACNA1BAPBA1NAMPTALDH1A1
SCHEMBL4161472 0.87 GSK3B (0.53) GSK3BCACNA1BAPBA1NAMPTALDH1A1
SCHEMBL4959799 0.86 GSK3B (0.42) GSK3BCACNA1BAPBA1NAMPTALDH1A1
SCHEMBL4162673 0.85 GSK3B (0.54) GSK3BNPC1RAB9AEGLN1
SCHEMBL4153424 0.85 NAMPT (0.55) GSK3BCACNA1BAPBA1NAMPTALDH1A1
SCHEMBL4154272 0.84 GSK3B (0.45) GSK3BCACNA1BAPBA1NAMPTALDH1A1
SCHEMBL4161610 0.83 GSK3B (0.43) GSK3BCACNA1BAPBA1NAMPTALDH1A1
SCHEMBL4154150 0.83 GSK3B (0.52) GSK3BALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL4157340 0.83 GSK3B (0.50) GSK3BCACNA1BAPBA1NAMPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US claimed
EP-1984370-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME Crystalgenomics, Inc. (KR) 2008-10-29 EP claimed
WO-2007083978-A1 IMIDAZOPYRIDINE DERIVATIVES INHIBITING PROTEIN KINASE ACTIVITY, METHOD FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME CRYSTALGENOMICS, INC. (KR) 2007-07-26 WO claimed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same YUYU PHARMA, INC. (KR) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170847-A1 Imidazopyridine Derivatives Inhibiting Protein Kinase Activity, Method for the Preparation Thereof and Pharmaceutical Composition Containing Same GSK3B, GSK3A, MAP3K3 GSK3B 1/4885CACNA1B 4611/4885APBA1 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.